Geert R. Kersten, Chief Executive Officer at CEL SCI CORP (CVM), bought 100,000 shares at $1.38 ($138K) on 2026-08-25, disclosed to the SEC on 2026-08-26.
CEO Geert R. Kersten purchased 100,000 shares at $1.38, signaling confidence in the stock's value despite recent capital raising efforts. This executive buy comes as the stock trades near its 52-week low, potentially offering a contrarian entry point.
The stock has plummeted 87.08% over the last year and is currently down 9.32% in the past five days, trading at $1.46 which is 89.17% below its 52-week high of $13.48.
1) Upcoming fiscal Q1 earnings on February 17, 2026, to review the reported $5.5 million loss. 2) The company announced a second equity raise for its cancer drug in just over a month, priced at a 7.4% discount to the previous close on June 15, 2026.
The company recently announced a second equity raise for its cancer drug in just over a month, which may dilute existing shareholders and signal funding concerns.
Nothing distinguishes this filing.
| Filing → |
| CVM | BUY | 2026-01-26 | $200K | — | Filing → |
| CVM | BUY | 2025-12-05 | $50K | — | Filing → |
| CVM | BUY | 2025-07-28 | $400K | — | Filing → |